Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer

NCT02015416 is registered in ClinicalTrials.gov with Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT02015416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02015416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
March 31, 2017
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, sarcoma